Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI

Market Cap	2.81M 0 2.46M 2.27M 2.08M 3.95M 270M 4.01M 27.05M 10.61M 132M 10.55M 10.32M 455M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-1.42M -0 -1.24M -1.14M -1.05M -1.99M -136M -2.02M -13.64M -5.35M -66.6M -5.32M -5.2M -230M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-11	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
01-25	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
01-13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
12-30	SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired.	CI
12-01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE
11-26	Scisparc to acquire treasury of patents for innovative medical endoscopy systems	RE
11-26	Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo	RE

07-15	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome	GL
06-05	SciSparc, Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	AQ
06-04	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	GL
05-28	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum	GL
04-22	AI Power Bottleneck Sparks Opportunity: Sphere 3D Corp. (NASDAQ: ANY) Emerging as Data Center Infrastructure Play	AQ

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	2022-01-09
Amitay Weiss CEO	Chief Executive Officer	62	2020-08-20
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	2016-02-07

Therapix Biosciences Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0010951403

Pharmaceuticals

Valuation: Therapix Biosciences Ltd

Latest news : Therapix Biosciences Ltd

Press Releases: Therapix Biosciences Ltd

News in other languages: Therapix Biosciences Ltd

Managers and Directors: Therapix Biosciences Ltd

Generic Pharmaceuticals

Financials

Company Profile

End-of-day quote TEL AVIV STOCK EXCHANGE Other stock markets
- ^ILa	-

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	2022-01-09
Itschak Shrem CHM	Chairman	79	2025-09-20
Lior Vider BRD	Director/Board Member	50	2020-08-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.46%	+2.53%	+15.98%	+81.88%	48.52B
OTSUKA HOLDINGS CO., LTD.	+1.00%	-0.99%	+67.75%	+112.99%	35.68B
CIPLA LIMITED	-0.01%	-0.95%	-3.10%	+39.49%	12.09B
ZYDUS LIFESCIENCES LIMITED	+2.06%	+0.34%	+19.46%	+94.32%	11.77B
KRKA, D. D.	+1.53%	+0.38%	+32.83%	+126.50%	9.19B
ONO PHARMACEUTICAL CO., LTD.	+0.40%	-3.70%	+44.27%	-4.88%	7.06B
GEDEON RICHTER	-0.17%	-2.20%	+18.33%	+37.26%	7.01B
GLENMARK PHARMACEUTICALS LIMITED	-0.33%	+1.43%	+3.52%	+227.22%	6.77B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+6.39%	-0.15%	-14.91%	+20.63%	5.98B
Average	+1.23%	+0.42%	+20.46%	+81.71%	16.01B
Weighted average by Cap.	+0.88%	-0.27%	+28.19%	+87.76%

	2024	2025
Net sales	1.31 0 1.14 1.05 0.97 1.83 125.67 1.87 12.58 4.93 61.42 4.9 4.8 211.71	0.86 0 0.75 0.69 0.63 1.2 82.37 1.22 8.24 3.23 40.26 3.21 3.14 138.76
Net income	-6.28M -0 -5.49M -5.07M -4.66M -8.83M -605M -8.98M -60.51M -23.74M -296M -23.6M -23.08M -1.02B	-12.18M -0 -10.65M -9.82M -9.03M -17.11M -1.17B -17.4M -117M -46.01M -573M -45.74M -44.73M -1.97B
Net Debt	-2.01M -0 -1.76M -1.62M -1.49M -2.83M -194M -2.87M -19.36M -7.6M -94.58M -7.55M -7.39M -326M	-4.22M -0 -3.69M -3.41M -3.13M -5.94M -407M -6.04M -40.68M -15.96M -199M -15.87M -15.52M -685M